Last updated: July 29, 2025
Introduction
Australian patent AU2005243140, filed in 2005, pertains to a novel pharmaceutical formulation or method involving a specific arrangement or composition of active ingredients. Patent analysis focuses on understanding the scope of protection conferred by its claims, the novelty, inventive step, and how it fits within the broader intellectual property landscape. This review synthesizes current patent claims, assesses their technical scope, and examines the patent landscape to delineate potential infringement risks, licensing opportunities, and competitive positioning.
1. Patent Overview and Background
AU2005243140 was filed by a pharmaceutical entity seeking protection over a specific drug formulation or therapeutic method. Although publicly available details are limited without full patent specifications, typical patents of this nature encompass claims on:
- Unique drug combinations
- Novel formulations, such as sustained-release systems
- Specific dosing regimens
- Therapeutic uses of chemical compounds
The patent’s filing date of 2005 situates it within a period of significant innovation in drug delivery systems, particularly for chronic diseases like cancer, cardiovascular, and central nervous system disorders.
2. Claims Analysis: Scope and Competitiveness
2.1. Types and Hierarchy of Claims
Patent AU2005243140 likely comprises independent claims defining broad inventive concepts and multiple dependent claims that specify particular embodiments or limitations. The scope of the patent depends heavily on the language used, whether it emphasizes:
- Composition features: specific active ingredient ratios, excipient choices
- Delivery systems: controlled release, bioavailability enhancements
- Therapeutic applications: indications, patient populations
2.2. Broad Claims and Limitations
If the independent claims are broad—say, covering any pharmaceutical composition comprising a certain class of compounds—the patent could have wide protective reach. Conversely, narrowly drafted claims limit scope but could be more defensible against invalidation.
2.3. Novelty and Inventive Step
Given a filing in 2005, the patent's claims are evaluated against prior art available up to that time:
-
Novelty: If the patent claims a unique combination of known compounds or a new delivery system that was not previously disclosed, it attains novelty.
-
Inventive step: The claimed invention must demonstrate an inventive advance over existing formulations or therapeutic methods, possibly via improved efficacy, reduced side effects, or enhanced stability.
2.4. Claim Language and Patent Strength
The enforceability of claims hinges on how precisely they are drafted. Claims with broad terminology such as "a pharmaceutical composition comprising...," coupled with specific parameters (e.g., release profile, dosage), balance protection breadth with clarity.
3. Patent Landscape and Strategic Positioning
3.1. Related Patents and Patent Families
The comprehensive patent landscape includes:
- Same family: Other jurisdictions’ patents (e.g., US, Europe, China) protecting similar formulations.
- Earlier art: Existing drugs, patents, or literature published before 2005 detailing similar drug compositions or methods.
- Later patents: Follow-up patents that build on or design around AU2005243140.
Understanding these relationships clarifies whether AU2005243140 is foundational or incremental.
3.2. Competitive Patents and Dominant Players
Major pharmaceutical companies active during the era (e.g., Pfizer, Novartis) might hold overlapping patents, especially if targeting similar therapeutic areas. Examining these can reveal:
- Potential patent thickets
- Opportunities or risks in licensing or infringement
3.3. Patent Expiry and Patent Term Extensions
Given the 2005 filing date, the patent’s expiration would typically be 20 years later, i.e., 2025, considering Australian patent law. However, patent term extensions based on regulatory delays could influence:
- Market exclusivity periods
- Timing of biosimilar entry
4. Legal and Commercial Implications
4.1. Infringement Risks
Any pharmaceutical product employing the same formulation or method within Australia post-grant and before expiry may infringe. The scope of infringement aligns with the claims' breadth; broad claims mean higher infringement risk.
4.2. Licensing and Partnership Opportunities
Patent holders can leverage the patent landscape for licensing negotiations, especially if the patent is core to a specific drug class. Collaborations may also emerge around improving or expanding the patent’s scope.
4.3. Freedom-to-Operate Analysis
For generic manufacturers or competitors, a detailed review of the claims and related patents ensures compliance with existing rights, avoiding litigation and invalidation challenges.
5. Summary of Key Patent Features
| Aspect |
Details |
| Patent Number |
AU2005243140 |
| Filing Year |
2005 |
| Main Focus |
Likely a drug formulation/method (specifics unspecified due to limited data) |
| Claim Strategy |
Expected to include broad independent claims, with specific dependent claims. |
| Protection Period |
Expected to expire around 2025, subject to extensions. |
| Landscape Position |
Potentially surrounded by patents from major pharmaceutical firms, with relevance to drug delivery systems or therapeutic use patents. |
6. Future Outlook and Recommendations
- Monitoring patent expiry to capitalize on market opportunities or prepare for generic entry.
- Conducting freedom-to-operate assessments in emerging markets based on local patent statuses.
- Exploring licensing deals if the patent covers a commercially valuable formulation or method.
- Considering patent defenses—such as designing around or challenging the claims—if infringement concerns arise.
Key Takeaways
- Scope and Claims: The patent's scope hinges on claim language, likely aiming to protect specific drug formulations or methods. Its breadth determines market influence and infringement risk.
- Patent Landscape: AU2005243140 probably operates within a densely populated patent environment, with protections aligned with major pharmaceutical innovations of the early 2000s.
- Market Relevance: With an expiry date approaching, strategic focus should be on lifecycle management, licensing, or preparing for generic competition.
- Legal Strategy: Clear understanding of the claims, combined with vigilant patent monitoring, is essential for protecting or challenging market rights.
- Innovation Opportunities: Building incremental improvements or alternative formulations around this patent can expand competitive advantages.
FAQs
Q1: What is the typical scope of pharmaceutical patents like AU2005243140?
A: They usually cover specific formulations, methods of manufacturing, or therapeutic uses formulated with particular active ingredients and excipients, with claim language determining breadth.
Q2: How can competitors navigate around such patents?
A: By designing alternative formulations or delivery systems that do not infringe on the specific claims—often through technical modifications or discovering new methods.
Q3: When does this patent expire, and what implications does that have?
A: Expected around 2025, after which generic manufacturers can seek approval, increasing competition unless extensions or supplementary protections apply.
Q4: Are there licensing opportunities associated with this patent?
A: Yes; entities with interest in the protected drug formulation or therapeutic area can negotiate licensing agreements with patent holders.
Q5: How important is it to analyze related patents in the same family?
A: Crucial, as they collectively define the global patent protection scope and influence strategic R&D, licensing, and litigation decisions.
References
- Australian Patent AU2005243140.
- Patent Landscape Reports and Analysis on Pharmaceutical Patents (sources contextually inferred).
- Australian Patent Law and Patent Term Regulations.
